Loading...
There is substantial disagreement on which patients without known cardiovascular disease (CVD) should take statins. In this latest effort to address potential benefits and harms of statins for primary prevention, a Swiss team created a complex model based on data from randomized trials and observational studies. The model also incorporated competing risks for non–CV-related death and results of a survey of patients' preferences for avoiding adverse CV outcomes and statin side effects.
The 10-year predicted CVD risk above which the model predicted net benefit ranged from 14% (for men in their 40s) to 21% (for 70- to 75-year-old men), and from 17% (for women in their 40s) to 22% (for 70- to 75-year-old women).